← Back to all trials
Active Not Recruiting
NCT06665412
Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
Conditions: Chronic Phase Ph+ Chronic Myeloid Leukemia
Sex: All
Ages: 19 Years – N/A
Healthy volunteers: No
Enrollment: 169
Sponsor: Il-Yang Pharm. Co., Ltd.
Location: Hallym University Sacred Heart Hosptial Anyang-si Gyeonnggi-do
Summary
The goal of this observational study is to learn about the efficacy and safety profile when Radotinib dose redution is performed in Ph+ CML subjects.
The main efficacy is checked by MMR rate by 12 months from IP treatment.
Eligibility Criteria
Inclusion Criteria:
1. Male or female patients aged 19 years old or older
2. Patients with confirmed diagnosis of chronic phase CML within last 8weeks(throung chromosome testing or bone marrow testing)
* Chronic phase CML is defined as follows:
* Blast in peripheral blood and bone marrow \
Source: ClinicalTrials.gov (NCT06665412). StuddyBuddy aggregates publicly available trial information.
